New York, NY - EMED Technologies, a global leader in drug delivery and innovative infusion therapy devices, announced the members of its Scientific Advisory Board (SAB). Established in 1991, EMED Technologies is a medical device company developing devices for subcutaneous infusion, supporting biologics, specialty drugs, and at-home treatments, ensuring patient independence, precision, comfort, and reliability.

"We have established a scientific partnership with these incredible doctors who embody what EMED is about. I am honored to work with such an exceptional Scientific Advisory Board on medical innovations, patient-centric technology, and clinical outcomes," said Alex Nikanorov, M.D., Ph.D., Director of Clinical Affairs of EMED Technologies.

The SAB includes leading academics Dr. Jeffrey Allen, a renowned neurologist in inflammatory neuropathy; Dr. Richard Wasserman, who specializes in immunodeficiency, asthma and allergy; and Dr. Jack Lewin, an expert in health innovation and health policy.

Using their considerable expertise and experience, the advisers will guide the Company and its leadership team on scientific and strategic matters - delivering patient-centric solutions that raise the standard for health and drug delivery. Their insights will support EMED's development of next-generation drug delivery systems for subcutaneous infusion.

The Scientific Advisory Board comprises:
Jeffrey Allen, M.D.: A neurologist providing care for patients with muscular dystrophy, neuropathy, Guillain-Barre Syndrome and many others. Dr. Allen is located at University of Minnesota Park Place East MINCEP Epilepsy Care and University of Minnesota Clinics and Surgery Center Neurology Clinic. He maintains clinical interests in myopathy and inflammatory diseases while also working as an Assistant Professor with the University of Minnesota Medical School's Department of Neurology and Professor Emeritus of Pediatrics and Neurology at NYU Langone Health.

Richard Wasserman, M.D., Ph.D.: A highly skilled, civic-minded allergist and immunologist with a specialized focus on food allergy and primary immunodeficiency treatments. He received his medical degree from the University of Texas Southwestern Medical School and completed his Pediatrics residency at the Children's Hospital of Philadelphia. Dr. Wasserman completed fellowship training in Bone Marrow Transplantation/Immunology at the Children's Hospital of Philadelphia, Postdoctoral Cancer/Immunology at the University of Texas Southwestern Medical School, and Immunology/Rheumatology at The Rockefeller University. He received his Ph.D. in Biomedical Sciences from the University of New York, Mt. Sinai School of Medicine.

Dr. Jack Lewin, M.D.: A principal and founder of Lewin and Associates LLC of New York City, Chairman of the National Coalition on Health (NCHC) of Washington DC, and CEO of Convergent Health Systems. Lewin and Associates is a consulting firm focused on advising health start-ups and policy development for health sector companies and government. The NCHC represents 90+ national health sector organizations and over 150 million Americans. Dr. Lewin is an internationally recognized expert in promoting a more efficient, effective, and sustainable healthcare system providing access to high-quality care for all. He has advised two Presidents of the United States.